SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence.
COVID-19
SARS-CoV-2
infectivity
mutants
severity
variants
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
15 Jun 2021
15 Jun 2021
Historique:
received:
26
04
2021
revised:
04
06
2021
accepted:
14
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
We conducted this review to summarize the relation between viral mutation and infectivity of SARS-CoV-2 and also the severity of COVID-19 in vivo and in vitro. Articles were identified through a literature search until 31 May 2021, in PubMed, Web of Science and Google Scholar. Sixty-three studies were included. To date, most studies showed that the viral mutations, especially the D614G variant, correlate with a higher infectivity than the wild-type virus. However, the evidence of the association between viral mutation and severity of the disease is scant. A SARS-CoV-2 variant with a 382-nucleotide deletion was associated with less severe infection in patients. The 11,083G > U mutation was significantly associated with asymptomatic patients. By contrast, ORF1ab 4715L and S protein 614G variants were significantly more frequent in patients from countries where high fatality rates were also reported. The current evidence showed that variants of concern have led to increased infectivity and deteriorating epidemiological situations. However, the relation between this variant and severity of COVID-19 infection was contradictory. The COVID-19 pandemic continues to spread worldwide. It is necessary to anticipate large clinical cohorts to evaluate the virulence and transmissibility of SARS-CoV-2 mutants.
Sections du résumé
BACKGROUND
BACKGROUND
We conducted this review to summarize the relation between viral mutation and infectivity of SARS-CoV-2 and also the severity of COVID-19 in vivo and in vitro.
METHOD
METHODS
Articles were identified through a literature search until 31 May 2021, in PubMed, Web of Science and Google Scholar.
RESULTS
RESULTS
Sixty-three studies were included. To date, most studies showed that the viral mutations, especially the D614G variant, correlate with a higher infectivity than the wild-type virus. However, the evidence of the association between viral mutation and severity of the disease is scant. A SARS-CoV-2 variant with a 382-nucleotide deletion was associated with less severe infection in patients. The 11,083G > U mutation was significantly associated with asymptomatic patients. By contrast, ORF1ab 4715L and S protein 614G variants were significantly more frequent in patients from countries where high fatality rates were also reported. The current evidence showed that variants of concern have led to increased infectivity and deteriorating epidemiological situations. However, the relation between this variant and severity of COVID-19 infection was contradictory.
CONCLUSION
CONCLUSIONS
The COVID-19 pandemic continues to spread worldwide. It is necessary to anticipate large clinical cohorts to evaluate the virulence and transmissibility of SARS-CoV-2 mutants.
Identifiants
pubmed: 34203844
pii: jcm10122635
doi: 10.3390/jcm10122635
pmc: PMC8232800
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cell. 2021 Jun 24;184(13):3426-3437.e8
pubmed: 33991487
Virology. 2021 Apr;556:96-100
pubmed: 33556653
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
EBioMedicine. 2021 Apr;66:103319
pubmed: 33840632
Emerg Microbes Infect. 2021 Dec;10(1):167-177
pubmed: 33399033
Sci Rep. 2021 Feb 26;11(1):4802
pubmed: 33637820
Viruses. 2021 Feb 02;13(2):
pubmed: 33540576
Infect Genet Evol. 2021 Jun;90:104734
pubmed: 33508515
Clin Microbiol Infect. 2021 May 24;:
pubmed: 34044152
Biochem Biophys Res Commun. 2021 Jan 29;538:104-107
pubmed: 33199022
Cell Discov. 2020 Oct 29;6(1):76
pubmed: 33298872
JAMA Netw Open. 2021 Apr 1;4(4):e217746
pubmed: 33900399
J Hum Genet. 2020 Dec;65(12):1075-1082
pubmed: 32699345
N Engl J Med. 2021 Apr 29;384(17):1671-1673
pubmed: 33725430
Pathogens. 2021 Feb 09;10(2):
pubmed: 33572190
EBioMedicine. 2020 Dec;62:103112
pubmed: 33186810
Postgrad Med. 2019 Jun;131(5):299-308
pubmed: 30845866
Nat Commun. 2020 Nov 26;11(1):6013
pubmed: 33243994
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Genomics Inform. 2020 Dec;18(4):e44
pubmed: 33412760
mBio. 2020 Oct 30;11(6):
pubmed: 33127862
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
Commun Biol. 2021 Feb 15;4(1):228
pubmed: 33589648
Front Microbiol. 2020 Jul 22;11:1800
pubmed: 32793182
Cell. 2021 Apr 29;184(9):2362-2371.e9
pubmed: 33735608
MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):717-718
pubmed: 33988184
Euro Surveill. 2021 Mar;26(12):
pubmed: 33769251
Int J Infect Dis. 2020 Jul;96:459-460
pubmed: 32464271
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Bull World Health Organ. 2020 Jul 1;98(7):495-504
pubmed: 32742035
Infect Genet Evol. 2021 Aug;92:104831
pubmed: 33798758
Euro Surveill. 2021 Mar;26(11):
pubmed: 33739254
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478621
PLoS One. 2020 Nov 17;15(11):e0242537
pubmed: 33201914
J Med Virol. 2020 Jun;92(6):667-674
pubmed: 32167180
BMJ. 2021 Mar 9;372:n579
pubmed: 33687922
J Mol Biol. 2020 Sep 4;432(19):5212-5226
pubmed: 32710986
Epidemiol Infect. 2020 Oct 26;148:e262
pubmed: 33100263
Rev Med Virol. 2004 Jan-Feb;14(1):17-31
pubmed: 14716689
Int J Clin Pract. 2020 Aug;74(8):e13525
pubmed: 32374903
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Clin Microbiol Infect. 2021 Jan 30;:
pubmed: 33524589
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
Nat Commun. 2020 Nov 25;11(1):5986
pubmed: 33239633
Int J Infect Dis. 2021 May;106:228-236
pubmed: 33785459
Infect Genet Evol. 2021 Jun;90:104730
pubmed: 33513449
Cell Res. 2021 Jun;31(6):720-722
pubmed: 33893398
Int J Antimicrob Agents. 2021 Feb;57(2):106272
pubmed: 33347989
Viruses. 2021 Apr 08;13(4):
pubmed: 33918060
Heliyon. 2020 Sep;6(9):e04658
pubmed: 32844125
Lancet Infect Dis. 2021 Apr 12;:
pubmed: 33857406
Lancet. 2020 Aug 29;396(10251):603-611
pubmed: 32822564
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
Viruses. 2021 Apr 07;13(4):
pubmed: 33917138
Int J Antimicrob Agents. 2020 Aug;56(2):106024
pubmed: 32450197
Travel Med Infect Dis. 2021 Mar-Apr;40:101980
pubmed: 33535105
J Travel Med. 2021 Feb 23;28(2):
pubmed: 33506254
Cell. 2020 Oct 29;183(3):739-751.e8
pubmed: 32991842
Emerg Microbes Infect. 2021 Dec;10(1):51-65
pubmed: 33306459
Transbound Emerg Dis. 2021 Jan 27;:
pubmed: 33506644
mBio. 2021 Jan 19;12(1):
pubmed: 33468702
J Phys Chem Lett. 2020 Dec 3;11(23):10007-10015
pubmed: 33179934
Science. 2020 Dec 18;370(6523):1464-1468
pubmed: 33184236
PLoS One. 2021 May 26;16(5):e0251426
pubmed: 34038453
Hum Genomics. 2021 Feb 3;15(1):10
pubmed: 33536081
PLoS One. 2020 Nov 18;15(11):e0241541
pubmed: 33206661
Viruses. 2021 Mar 01;13(3):
pubmed: 33804556
Nature. 2020 Jul;583(7816):437-440
pubmed: 32434211
MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):712-716
pubmed: 33983915